A Study to Evaluate the Safety and Tolerability of EXN407

  • End date
    May 20, 2022
  • participants needed
  • sponsor
    Exonate Limited
Updated on 23 June 2021
Mike Taylor
Primary Contact
Centre for Eye Research Australia (CERA) (5.9 mi away) Contact
+9 other location


This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked, vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and tolerability of EXN407 in subjects with centre involved Diabetic Macular Oedema (DMO), with Centre-subfield macular thickness (CMT) between 280-420 m and Best corrected visual acuity (BCVA) better than approximate Snellen equivalent 20/32 (6/9, 78 letters) in the study eye, which is considered secondary to diabetes mellitus. For brevity, the BCVA criteria will be noted as 20/32 (6/9).

This study will provide a basis for further clinical development of EXN407 ophthalmic solution.

Condition Diabetic Macular Edema
Treatment EXN407
Clinical Study IdentifierNCT04565756
SponsorExonate Limited
Last Modified on23 June 2021


Yes No Not Sure

Inclusion Criteria

Subject is at least 18 years of age inclusive, at the time of signing the informed consent
BCVA better than approximate Snellen equivalent 20/32 (6/9, 78 letters) in the study eye using the ETDRS visual acuity scale at Screening. Subjects should have less than a 10% variance in this measure at Screening and baseline visit
Ocular media is consistent with SD-OCT imaging and cataracts are not expected in the subject for the duration of the study
The subject has no other retinal disease
Subject or the subject's partner successfully demonstrates their ability to self-administer/administer eye drops at Screening, with multiple attempts allowed at the discretion of the Investigator

Exclusion Criteria

Any other retinal disease in the study eye, other than centre involved DMO or diabetic retinopathy
Poor vision (VA 6/60 or worse) in the contralateral eye
Intraocular inflammation (including trace or greater) in the study eye. History of idiopathic or autoimmune uveitis in either eye
Prior or current use of intravitreal ranibizumab, bevacizumab, aflibercept or the use of systemic or intraocular steroids in either eye
Within 180 days prior to the Screening visit, use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, and ethambutol)
History of (within 90 days of Screening date) cerebral vascular accident (stroke) or MI
Significant renal impairment including subjects on chronic renal dialysis and subjects with a history of nephrectomy or kidney transplant (regardless of renal function)
History of anaphylaxis, anaphylactoid (resembling anaphylaxis) reactions, or severe allergic responses
Positive pregnancy test (all female subjects of childbearing potential must have a urine -human chorionic gonadotropin [hCG] pregnancy test performed at Screening and within 7 days prior to randomisation) or is known to be pregnant or lactating
Known to have, or history of a positive test result for, hepatitis B or C, HIV, syphilis, tuberculosis, or COVID-19
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note